 However, the mutation of KRAS and EGFR are generally mutually exclusive.Lung cancer patients who are positive for KRAS mutation (and the EGFR status would be wild type) have a low response rate to erlotinib or gefitinib estimated at 5% or less.Different types of data including mutation status and gene expression did not have a significant prognostic power.